However, the application of anti-VEGF drugs was restricted by several problems, including short duration of action, requirement for repeated injections, complications such as endophthalmitis, lens damage, retinal detachment, high intraocular pressure, and drug resistance, and all the above problems limited the efficacy of anti-VEGF drugs [3–6]. The gene discussed is VEGFA; the disease is retinal detachment.